Our work in anaplastic thyroid cancer suggests that TRβ agonists can be combined with modulators of PI3K, MAPK, and CDK signaling to enhance their efficacy [79] and highlights the possibility that TRβ could be used as a molecular target for therapeutic intervention. Here, THRB is linked to thyroid gland undifferentiated (anaplastic) carcinoma.